CN108341881A - Chimeric antigen receptor and its expressing gene with safety switch, the NK cells of its modification and application - Google Patents

Chimeric antigen receptor and its expressing gene with safety switch, the NK cells of its modification and application Download PDF

Info

Publication number
CN108341881A
CN108341881A CN201810096080.3A CN201810096080A CN108341881A CN 108341881 A CN108341881 A CN 108341881A CN 201810096080 A CN201810096080 A CN 201810096080A CN 108341881 A CN108341881 A CN 108341881A
Authority
CN
China
Prior art keywords
chimeric antigen
antigen receptor
seq
gly
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810096080.3A
Other languages
Chinese (zh)
Other versions
CN108341881B (en
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Morecell Biomedical Technology Development Co Ltd
Original Assignee
Shenzhen Morecell Biomedical Technology Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Morecell Biomedical Technology Development Co Ltd filed Critical Shenzhen Morecell Biomedical Technology Development Co Ltd
Priority to CN201810096080.3A priority Critical patent/CN108341881B/en
Publication of CN108341881A publication Critical patent/CN108341881A/en
Application granted granted Critical
Publication of CN108341881B publication Critical patent/CN108341881B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a kind of Chimeric antigen receptor with safety switch and its expressing gene, the NK cells of its modification and applications.The Chimeric antigen receptor includes sequentially connected first signal peptide, c Met single-chain antibodies, CD8 structural domains, 41BB intracellular domain, DAP12 ITAM structural domains, T2A, second signal peptide and the EGFRt of transformation.The experimental results showed that the NK cells of above-mentioned Chimeric antigen receptor modification, Chimeric antigen receptor immune response is controllable, has a safety feature, and treatment side effect is few, and specificity is high.

Description

The NK cells of Chimeric antigen receptor and its expressing gene with safety switch, its modification And application
Technical field
The present invention relates to biotechnologies, more particularly to a kind of Chimeric antigen receptor with safety switch and its expression Gene, the NK cells of its modification and application.
Background technology
The human world matter epidermis transforming factor c-Met (Mesenchymal Epithelial Transition Factor, c- Met) be hepatocyte growth factor (Hepatocyte Growth Factor, HGF) receptor, it is super to belong to tyrosine kinase receptor Family member.C-Met activates HGF/c-Met signal paths, reduces intercellular adhesive force, be conducive to swell by being combined with HGF The transfer of oncocyte.Recent study finds that c-Met is in the higher liver cancer of China's incidence, lung cancer, breast cancer, gastric cancer, pancreas Overexpression, mutation or activity change are presented in the tumor tissues such as cancer, glioma.Therefore, c-Met has become antitumor One important target spot for the treatment of.
In recent years in adoptive cell therapy technology, Chimeric antigen receptor (chimeric antigen receptor, CAR) T cell (CAR-T) technology modified achieves significant breakthrough in the clinical application for the treatment of tumour, in clinical test Good targeting, lethal and persistence are shown, huge application potential and development prospect are illustrated.But it is traditional The T cell of Chimeric antigen receptor modification, cannot start or stop performance immunization as needed, and treatment side effect is more, special Property is poor.It finds that CAR-T technologies have in newest clinical trial and causes the high wind such as cytokine storm and systemic neurotoxicity Dangerous factor.
Natural killer cells (Natural Killer Cell, NK cell) is the core component of human body congenital immunity, It is that the third monoid lymphocyte arranged side by side with T, B cell is reached maturity from candidate stem cell in marrow.NK cells have There are many features：Inherent immunity cell, non-specific direct killing target cell, need not in advance by antigen sensibilization, need not resist Body participates in, is restricted without MHC, playing immunologic cytotoxicity effect early.Therefore, with Chimeric antigen receptor modification NK cells at For new antitumor research direction.
However, that there are security performances is poor, treatment side effect is more, specifically for the NK cells of traditional Chimeric antigen receptor modification The problems such as property is poor.
Invention content
Based on this, it is necessary to provide a kind of NK cells that can be modified, and make the security performance of the NK cells after modification It gets well, treatment side effect is few, specificity high Chimeric antigen receptor and its expressing gene with safety switch.
In addition, also providing the band that a kind of expression vector and a kind of security performance are preferable, treatment side effect is few, specificity is high The NK cells of the Chimeric antigen receptor modification of safety switch and its application.
A kind of Chimeric antigen receptor with safety switch, including sequentially connected first signal peptide, c-Met single-chain antibodies, CD8 structural domains, 41BB intracellular domain, DAP12-ITAM structural domains, T2A, second signal peptide and the EGFRt of transformation；Wherein, The amino acid sequence of the c-Met single-chain antibodies is as shown in SEQ ID No.1, and the amino acid sequence of the EGFRt of the transformation is such as Shown in SEQ ID No.2.
In one embodiment, the nucleotide sequence of the c-Met single-chain antibodies is encoded as shown in SEQ ID No.3.
In one embodiment, the nucleotide sequence of the EGFRt of the transformation is encoded as shown in SEQ ID No.4.
In one embodiment, the Chimeric antigen receptor is：
(a) protein that amino acid sequence forms shown in SEQ ID No.5；Or,
(b) by replacing, missing or adding one or several amino acid in the amino acid sequence shown in SEQ ID No.5 And there is the active protein derived from (a) of the Chimeric antigen receptor.
In one embodiment, the Chimeric antigen receptor is：
(a) the nucleotide sequence coded obtained protein shown in SEQ ID No.6；Or,
(b) in the nucleotide sequence shown in SEQ ID No.6 through replacing, missing or adding one or several bases and Can encode to obtain has the active protein derived from (a) of the Chimeric antigen receptor.
A kind of expressing gene, for expressing the Chimeric antigen receptor with safety switch, the Chimeric antigen receptor include according to First signal peptide of secondary connection, c-Met single-chain antibodies, CD8 structural domains, 41BB intracellular domain, DAP12-ITAM structural domains, The EGFRt of T2A, second signal peptide and transformation；Wherein, the amino acid sequence of the c-Met single-chain antibodies such as SEQ ID No.1 Shown, the amino acid sequence of the EGFRt of the transformation is as shown in SEQ ID No.2.
In one embodiment, the expressing gene is：
(a) nucleotide sequence as shown in SEQ ID No.6；Or,
(b) in the nucleotide sequence shown in SEQ ID No.6 through replacing, missing or adding one or several bases and Can encode to obtain has the active nucleotide sequence of the Chimeric antigen receptor.
A kind of expression vector contains above-mentioned expressing gene in the expression vector.
A kind of NK cells of the Chimeric antigen receptor modification with safety switch, can express in the NK cells any of the above-described Chimeric antigen receptor described in has either imported expressing gene described in any one of the above embodiments or described in the NK cells Above-mentioned expression vector has been transfected in NK cells.
Chimeric antigen receptor described in any one of the above embodiments, expressing gene as described in any one of the above embodiments, the table described in above-mentioned 8 Up to carrier or NK cells the answering in preparing anti-tumor drug of the above-mentioned Chimeric antigen receptor modification with safety switch With.
Above-mentioned Chimeric antigen receptor includes sequentially connected first signal peptide, c-Met single-chain antibodies, CD8 structural domains, 41BB Intracellular domain, DAP12-ITAM structural domains, T2A, second signal peptide and the EGFRt of transformation.Utilize the anti-c-Met of screening The surface growth factor of transformation is added as the scFv sequences in Chimeric antigen receptor (CAR) carrier in monoclonal antibody sequences Receptor (EGFRt).Its structure of the EGFRt of transformation only includes extracellular domain III, extracellular domain IV and the transmembrane structure of EGFR Domain does not include intracellular tyrosine kinase domain.Extracellular domain III in the EGFRt of transformation is (shown in SEQ ID No.2 No. 1 amino acid~No. 172 amino acid) and (No. 173 amino acid~312nd shown in SEQ ID No.2 extracellular domain IV Number amino acid) be Cetuximab binding site.The experimental results showed that above-mentioned Chimeric antigen receptor can be steady in NK cells Fixed expression, to form the NK cells of Chimeric antigen receptor modification.And the Chimeric antigen receptor can target c-Met, and carry Safety switch, Chimeric antigen receptor structure and EGFRt constructions of switch are expressed in NK cell surfaces respectively with autothermic cracking peptide T 2A. Cytokine storm and system are generated after the NK cells (CAR-NK cells) of above-mentioned Chimeric antigen receptor modification are transfused to patient When the side effects such as nerve toxicity, then Cetuximab is commercialized in injectable, is acted on, can be removed by the ADCC of NK cells itself Internal genetic engineering transformation is to express the natural killer cells of CAR.Therefore Cetuximab can be used as chimeric antigen in NK cells " switch " of receptor behavior realizes that Chimeric antigen receptor immune response is controllable, has a safety feature that treatment side effect is few, specificity It is high.
Description of the drawings
Fig. 1 is the structural schematic diagram of the c-Met Chimeric antigen receptors with EGFRt switches in embodiment 1；
Fig. 2 is the plasmid table of the slow virus expression plasmid pLenti7.3-c-Met/CAR-EGFRt built in embodiment 1 Figure；
Fig. 3 is the electrophoresis knot of slow virus expression plasmid pLenti7.3-c-Met/CAR-EGFRt digestion products in embodiment 1 Fruit is schemed；
The expression quantity of detection c-Met after Fig. 4 behaviours HepG-2 cell and normal liver cell L-O2 cell crackings Western Blotting testing result figures；
Fig. 5 is the NK cells Cytotoxicity in vitro cell at different conditions of the Chimeric antigen receptor modification obtained in embodiment 1 Streaming scatterplot result comparison chart；
Fig. 6 is the system of the NK cells Cell viability at different conditions of the Chimeric antigen receptor modification obtained in embodiment 1 Count result comparison chart.
Specific implementation mode
In order to make the foregoing objectives, features and advantages of the present invention clearer and more comprehensible, with reference to specific embodiment and Attached drawing is described in detail the specific implementation mode of the present invention.Elaborate in the following description many details in order to Fully understand the present invention.But the invention can be embodied in many other ways as described herein, art technology Personnel can do similar improvement without violating the connotation of the present invention, therefore the present invention is not by following public specific implementation Limitation.
The Chimeric antigen receptor (CAR) with safety switch of one embodiment, including sequentially connected first signal peptide, c- Met single-chain antibodies, CD8 structural domains, 41BB intracellular domain, DAP12-ITAM structural domains, T2A, second signal peptide and transformation EGFRt.Wherein, the amino acid sequence of c-Met single-chain antibodies is as shown in SEQ ID No.1, the amino acid sequence of the EGFRt of transformation Row are as shown in SEQ ID No.2.
Specifically, using the monoclonal antibody sequences of the anti-c-Met of screening, the sequence of wherein VH and VL are selected, for setting The scFv sequences in CAR carriers are counted, the amino acid sequence of the c-Met single-chain antibodies as shown in SEQ ID No.1 is obtained.Wherein, No. 1 amino acid~No. 97 amino acid is VH (heavy chain) sequence, No. 98 amino acid~No. 112 ammonia in SEQ ID No.1 Base acid is connection peptide, and No. 113 amino acid~No. 218 amino acid is VL (light chain) sequence.
Further, codon optimizes, and obtains the nucleotide sequence such as SEQ ID of coding c-Met single-chain antibodies Shown in No.3.
Specifically, the amino acid of the EGFRt of transformation only include EGFR extracellular domain III, extracellular domain IV and across Spanning domain does not include intracellular tyrosine kinase domain.Extracellular domain III (SEQ ID No.2 in the EGFRt of transformation Shown in No. 1 amino acid~No. 172 amino acid) and extracellular domain IV (No. 173 amino acid shown in SEQ ID No.2 ~the No. 312 amino acid) be Cetuximab binding site, be capable of specificity combination Cetuximab.
Further, codon optimizes, and obtains the nucleotide sequence such as SEQ ID No.4 of the EGFRt of coding transformation It is shown.
In present embodiment, Chimeric antigen receptor is：(a) egg that amino acid sequence forms shown in SEQ ID No.5 White matter；Or, (b) by replacing, missing or adding one or several amino acid in the amino acid sequence shown in SEQ ID No.5 And there is the active protein derived from (a) of Chimeric antigen receptor.
Specifically, in amino acid sequence shown in SEQ ID No.5, No. 1 amino acid~No. 22 amino acid is first Signal peptide, No. 23 amino acid~No. 240 amino acid are c-Met single-chain antibodies, No. 245 amino acid~No. 315 amino Acid is CD8 structural domains (including hinge area and transmembrane domain), and No. 316 amino acid~No. 357 amino acid is 41BB intracellulars Structural domain (costimulatory signal intracellular domain), No. 358 amino acid~No. 405 amino acid are DAP12-ITAM structural domains (DAP12 immunoreceptor tyrosine activating motif ITAM structural domains), No. 410 amino acid~No. 430 amino acid are T2A (oneself Crack polypeptide), No. 431 amino acid~No. 452 amino acid is second signal peptide, No. 453 amino acid~No. 787 amino Acid is the EGFRt of transformation.In addition, there are two restriction enzyme site (No. 241 amino acid~No. 244 ammonia in Chimeric antigen receptor Base acid and No. 406 amino acid~No. 409 amino acid).
Further, Chimeric antigen receptor is：(a) the nucleotide sequence coded obtained egg shown in SEQ ID No.6 White matter；Or, (b) in the nucleotide sequence shown in SEQ ID No.6 through replacing, missing or adding one or several bases and It can encode to obtain with the active protein derived from (a) of Chimeric antigen receptor.
It is appreciated that there are many codons due to the same amino acid of coding, the coded sequence of polypeptide has polymorphism And the characteristics of variation.Therefore one or several by replacing, missing or adding in the amino acid sequence shown in SEQ ID No.5 Amino acid and there is the active protein of Chimeric antigen receptor recombinant antigen, or the nucleotide sequence shown in SEQ ID No.6 Middle process replaces, misses or adds one or several bases and can encode to obtain with the active derivative egg of recombinant antigen In vain, the albumen obtained does not have apparent function difference with Chimeric antigen receptor, is intended to be included within the scope of the present invention.
By continuous research and probe, successful design goes out the Chimeric antigen receptor with safety switch of above-mentioned functional structure (CAR).The Chimeric antigen receptor (CAR) with safety switch, including sequentially connected first signal peptide, c-Met single-chain antibodies, CD8 structural domains, 41BB intracellular domain, DAP12-ITAM structural domains, T2A, second signal peptide and the EGFRt of transformation.This is embedding Antigen receptor is closed experiment proves that c-Met can be targeted, and carries safety switch, Chimeric antigen receptor structure and EGFRt switches Structure is expressed in NK cell surfaces respectively with autothermic cracking peptide T 2A.As the NK cells (CAR-NK of above-mentioned Chimeric antigen receptor modification Cell) it is transfused to after patient when generating the side effects such as cytokine storm and systemic neurotoxicity, then injectable commercialization west Appropriate former times monoclonal antibody is acted on by the ADCC of NK cells itself, and it is thin to express the natural kill of CAR can to remove internal genetic engineering transformation Born of the same parents.
The above-mentioned Chimeric antigen receptor (CAR) with safety switch can be used in anti-tumor drug.
In addition, the application also provides the expressing gene of an embodiment, the expressing gene is for expressing with safety switch Chimeric antigen receptor.
Specifically, the feature of Chimeric antigen receptor refers to described above, and therefore not to repeat here.
Specifically, which is：(a) nucleotide sequence as shown in SEQ ID No.6；Or, (b) in SEQ ID By replacing, missing or adding one or several bases and can encode to obtain with chimeric in nucleotide sequence shown in No.6 The active nucleotide sequence of antigen receptor.
Above-mentioned expressing gene can express the Chimeric antigen receptor (CAR) with safety switch, and the Chimeric antigen receptor is through examination Verification can target c-Met, and carry safety switch, can stablize in NK cells and express, have a safety feature, treating secondary work With less, specificity it is good.
Above-mentioned expressing gene can be used in anti-tumor drug.
In addition, the application also provides the expression vector of an embodiment, above-mentioned expressing gene is contained in the expression vector.
In one embodiment, which is the slow virus containing above-mentioned expressing gene.
The expression vector can be used in expressing above-mentioned Chimeric antigen receptor, and expression efficiency is high, and expression quantity is stablized, and can use In anti-tumor drug.
In addition, the application also provides a kind of NK cells of Chimeric antigen receptor modification of the embodiment with safety switch.It should NK cells can express above-mentioned Chimeric antigen receptor and either import above-mentioned expressing gene or the NK in the NK cells Above-mentioned expression vector has been transfected in cell.
Specifically, the feature of Chimeric antigen receptor refers to described above, and therefore not to repeat here.
The experimental results showed that the NK cells against tumor of the above-mentioned Chimeric antigen receptor modification with safety switch has specificity Efficient killing effect effect.And it is generated after the NK cells (CAR-NK cells) of above-mentioned Chimeric antigen receptor modification are transfused to patient thin When the side effects such as intracellular cytokine storm and systemic neurotoxicity, then Cetuximab is commercialized in injectable, passes through NK cells itself ADCC effects, the transformation of internal genetic engineering can be removed to express the natural killer cells of CAR.Therefore Cetuximab can be used as " switch " of Chimeric antigen receptor behavior in NK cells is realized that Chimeric antigen receptor immune response is controllable, is had a safety feature, treat Few side effects, specificity is high, can be used in anti-tumor drug.
It is specific embodiment part below.
In following embodiment, unless otherwise instructed, test method without specific conditions, usually according to normal condition, For example, see Pehanorm Brooker, EF, not the written molecular cloning of Ritchie, T Mannies A Disi etc. (Jin Dongyan, Li Mengfeng etc. are translated) is real Test (the Beijing guide [M]：Science Press, 1992) method that condition or kit manufacturer described in are recommended is realized. Reagent used in embodiment is commercially available.Unit mM indicates that mmol/L, M indicate mol/L.
Embodiment 1
1, the structure of the c-Met Chimeric antigen receptor slow virus carriers with EGFRt switches
1.1 c-Met scFv sequences
Using the monoclonal antibody sequences of the anti-c-Met of this laboratory screening, the sequence of wherein VH and VL are selected, for setting Count the scFv sequences in CAR carriers.
The 1.2 c-Met CAR sequent synthesis with EGFRt switches
According to the sequence of CAR each components, cut with scissors containing signal peptide SP, c-Met single-chain antibody (scFv), CD8 in full length sequence Sequence and transmembrane domain, 41BB intracellular domain and DAP12-ITAM structural domains, T2A, signal peptide SP, EGFRt, are collectively referred to as SP-c-Met scFv-CD8-41BB-DAP12-T2A-SP-EGFRt, structure chart are as shown in Figure 1.At entire frame 5 ' end and 3 ' Restriction enzyme site EcoR I and XhoI are added in end respectively, and commission Nanjing Genscript Biotechnology Co., Ltd. synthesizes whole table Up to frame, the sequence after synthesis is cloned in pUC57 carriers (as shown in SEQ ID No.6), and plasmid is named as pUC57-c-Met/ CAR-EGFRt。
The structure of 1.3 c-Met/CAR-EGFRt sequence Gateway entry clones
(1) pUC57-c-Met/CAR-EGFRt plasmids and Gateway entry vector pENTR 11vector use EcoR respectively I/Xho I double digestions, system are as shown in table 1 below.
Table 1：Digestion system
Plasmid or carrier 1ng
EcoR I 1μL
Xho I 1μL
10×Buffer 5μL
DdH is added2O is to total volume 50μL
Digestion condition：2h is digested in 37 DEG C of water-baths.
(2) glue recycles large fragment after c-Met/CAR-EGFRt segments and 11 carrier digestions of pENTR respectively.
(3) c-Met/CAR-EGFRt segments are connected with 11 carrier segments of pENTR, and system is as shown in table 2 below.
Table 2：Linked system
10×T4 DNA ligase buffer 2.5μL
C-Met/CAR-EGFRt segments 0.3pmol
11 carrier segments of pENTR 0.03pmol
T4DNA ligase 1μL
DdH is added2O is to total volume 25μL
Condition of contact：16 DEG C connect 12 hours.
(4) it takes connection product to convert into DH5 α competent bacterias, places and be incubated overnight in 37 DEG C of bacteriological incubators, picking Single bacterium colony expands culture, extracts the plasmid of positive colony, identified through digestion, and correct Gateway Entry clone plasmids are ordered Entitled pENTR-c-Met/CAR-EGFRt.
The structure of 1.4 pLenti7.3-c-Met/CAR-EGFRt slow virus expression plasmids
(1) LR reacts
LR reactions are entry clones pENTR-c-Met/CAR-EGFRt and purpose carrier pLenti7.3/V5-DEST The recombining reaction that vector occurs obtains slow virus expression plasmid pLenti7.3-c-Met/CAR-EGFRt, matter after recombination Grain spectrogram is as shown in Figure 2.
LR reaction systems are as shown in table 3 below.
Table 3：LR reaction systems
PENTR-c-Met/CAR-EGFRt (150ng/ reactions) 1 μ of μ L~7 L
pLenti7.3/V5-DEST vector(150ng/μl) 1μL
TE Buffer, pH 8.0 Add to 8 μ L of total volume
It thaws on iceLR ClonaseTMII Plus Enzyme Mix draw 2 μ l and add to above-mentioned LR reactions In system, after soft mixing, 25 DEG C of placement 1h.1 μ L Proteinase Ks are added to above-mentioned reaction system, 37 DEG C of incubation 10min.
(2) in the conversion of LR reaction products to DH5 α competent bacterias, step is same as above.
(3) screening and amplification of positive colony
A) after dips 3 clones with pipette tips on a small quantity respectively, pipette tips is placed in 10 μ L sterile waters, are blown and beaten repeatedly.
B) draws 1 μ L bacterium solutions and is used for PCR, and reaction system and condition are as shown in table 4 below.
Table 4：The amplification reaction system of positive colony
Bacterium solution 1μL
AttB1 primers (20 μM) 1μL
V5 reverse primers (20 μM) 1μL
Bio-rad super mix 6.25μL
ddH2O 15.75μL
Total volume 25μL
Reaction condition is as shown in table 5 below.
Table 5：The amplification reaction condition of positive colony
C) PCR product of tri- clones of is reacted into row agarose gel electrophoresis, if being obtained at 2.6kb clearly single The positive colony identified is then chosen in the LB culture solutions containing ampicillin and is enlarged culture by band.
D) extracts plasmid, obtains slow virus expression plasmid pLenti7.3-c-Met/CAR-EGFRt, while preserving strain. Three clones on random picking LB tablets carry out PCR amplification with attB1 primers and V5 reverse primers, and product passes through agarose Gel electrophoresis identifies occur clearly band (Fig. 3) at 2.6kb, illustrate that c-Met/CAR-EGFRt genes are successfully plugged into In pLenti7.3/V5-DEST expression vectors.
It is prepared by the packaging of the c-Met Chimeric antigen receptor slow virus 2, with EGFRt switches
2.1 Day1：Take 5 × 106A 293FT cells (Invitrogen, Cat.No.R700-07), supernatant is abandoned after centrifugation, With the complete medium of 37 DEG C of 10mL preheating (D-MEM+10%FBS+2mM L-Glutamine+0.1mM nonessential amino acids+ 1mM Sodium Pyruvates+1%P/S) it is resuspended, it is inoculated in 10cm culture dishes, 37 DEG C, 5%CO2It is incubated overnight in incubator.
2.2Day2：The culture solution in culture dish is discarded, Opti-s of the 5mL containing 10%FBS is addedI culture solutions (Invitrogen,Cat.No.31985-062)。
2.3DNA-The preparation of 2000 compounds
(a) is by the Opti- of 1.5mL serum-freesI culture solutions are added in 5mL centrifuge tubes, and 9 μ g are added ViraPowerTMPackaging plasmid mixture and 3 μ g slow virus expression plasmid pLenti7.3-c-Met/CAR-EGFRt, it is soft mixed It closes.
(b) is by the Opti- of 1.5mL serum-freesI culture solutions are added in another 5mL centrifuge tube, and 36 μ L are added2000, it is incubated at room temperature 5min after soft mixing.
(c) solution that (a), (b) two step obtain is transferred in a centrifuge tube by, soft to be uniformly mixed.
(d) is incubated 20min at room temperature, obtains DNA-2000 compounds.
2.4 DNA- that will be obtained2000 complexes drop-wises are slowly added into culture dish, and gently Culture dish is shaken back and forth in ground.37 DEG C, 5%CO2It is incubated overnight in incubator.
2.5 Day3：Culture dish is taken out, culture solution is discarded, 10mL DMEM complete mediums are added.37 DEG C, 5%CO2Training It supports and is incubated 48h~72h in case.
2.6 Day5 or Day6：Culture solution in culture dish is transferred in 15mL centrifuge tubes, 2000g under the conditions of 4 DEG C Centrifuge 15min.
2.7 Aspirate supernatants are collected pLenti7.3-c-Met/CAR-EGFRt slow virus, are distributed into 1mL cryopreservation tubes, It is placed in -80 DEG C of long-term preservations.
3, the preparation of the c-Met specific C AR-NK cells with EGFRt switches
3.1 separating health volunteer's PBMC cells
(1) healthy volunteer peripheral blood 25mL, anticoagulant heparin are extracted, room temperature centrifuges (700g, 20min)；Draw upper layer blood Slurry, is placed in water-bath 56 DEG C, 30min；Then it after 4 DEG C of standing 15min, centrifuges (900g, 30min), takes 4 DEG C of guarantors of autologous plasma It deposits spare.
(2) above-mentioned 700g, 20min is taken to centrifuge rear lower cell component, D-PBS to 50mL, mixing is added to be added slowly to be equipped with In the 50mL centrifuge tubes of 20mL human lymphocyte separating liquids, room temperature centrifuges (800g, 15min).
(3) tunica albuginea confluent monolayer cells are drawn, are added in the 50mL centrifuge tubes equipped with 5mL RPMI 1640.
(4) RPMI 1640 washes twice (600g, 10min are centrifuged), and it is PBMC cells to collect cell.
The preparation of 3.2 CAR-NK cells
(1) with the monoclonal antibodies of CD16 containing 50ng/mL, 1000U/mL IL-2,100ng/mL IL-15 and 0.5% autologous plasma It is 1 × 10 that Alys505 culture solutions, which adjust PBMC cell densities,6/ mL is transferred in six orifice plates, and the holes 2mL/ are placed in saturated humidity, 37 DEG C, cultivate in 5.0%CO2 incubators.
(2) every 3 days adjustment cell densities are 1 × 106/ mL adds IL-2 containing 1000U/mL and 0.5% autologous plasma Alys505 culture solutions.
(3) the 7th days, NK cells are divided into 2 groups, every group of cell presses 1 × 105The density in/hole is transferred in 24 orifice plates, 100 holes μ L/, every group sets three multiple holes.
1st group：PLenti7.3-c-Met/CAR-EGFRt is transfected, c-Met/CAR-EGFRt groups are named as.According to MOI values =20 (ratios of MOI expressions herein viral number and cell quantity) are added sick slowly containing pLenti7.3-c-Met/CAR-EGFRt The stoste of malicious particle takes slow virus solution that Alys505 complete mediums is added to be configured to 100 μ L altogether, with pipette that slow virus is molten Liquid adds in cell, gently blows and beats mixing.
2nd group：Blank NK cell controls groups, are named as NC groups.
Every group of Polybrene for being separately added into final concentration of 6 μ g/mL, gently shakes after mixing, is placed in 37 back and forth DEG C, 5%CO2It is incubated for 24 hours in incubator.
8th day, cell took out centrifugation, discards the supernatant containing slow virus, is resuspended, is added with 200 μ L Alys-505 culture solutions Enter in 24 orifice plates.Fluid infusion is carried out according to cell growth state.
It 10th day, harvests ripe cell and is used for subsequent analysis.
Test one：
The expression of c-Met in Western Blotting detection tumour cells
The human liver cancer cell HepG-2 and normal liver cell L-O2 for choosing exponential phase, with cell protein extracts reagent (RIPA) lytic cell extracts cell protein, carries out Western Blotting detections.The results are shown in Figure 4, liver cancer cells HepG-2 detects the expression of c-Met, and normal liver cell L-O2 can't detect the expression of c-Met.Illustrate have in liver cancer cells C-Met is expressed.
Test two：
C-Met specific C AR-NK cells in vitro antitumor activities detection with EGFRt switches
(1) the c-Met/CAR-EGFRt groups cell and NC groups cell prepared using embodiment 1 as effector cell, The HepG-2 cell and normal liver cell L-O2 of CFSE labels are as target cell, according to 20:1 effect target is thinner than melange effect Born of the same parents and target cell, gently mixing, is placed in 5%CO2, it is incubated in 37 DEG C of incubators.
(2) after for 24 hours, 1 μ g/mL PI dye liquors, mixing is added and is examined using flow cytometer after room temperature is protected from light incubation 15min Survey CFSE+PI+The percentage of cell (dead HepG-2 cells and L-O2 cells).
Specifically, using each group cell as effector cell, with CFSE labelling liver cancer cells HepG-2 and normal liver cell L- O2, as target cell, the killing using Flow cytometry NK cells to HepG-2 cell line and normal liver cell L-O2 Efficiency, experimental result is as shown in figure 5, c-Met/CAR-EGFRt groups cell is about to the killing rate of HepG-2 cell line 72.93%, NC group cell are about 24.87%, c-Met/CAR-EGFRt group cells to just to the killing rate of HepG-2 cell line It is about 1.7% to the killing rate of normal liver cell L-O2 that the killing rate of normal liver cell L-O2, which is about 1.2%, NC groups cell,.Explanation C-Met specific C AR-NK cells prepared by embodiment 1 have efficient lethal effect to liver cancer cells, and to normal liver cell Without lethal effect.
Test three：
EGFRt switchs efficiency assay
By c-Met/CAR-EGFRt groups cell and NC groups cell respectively according to 1 × 105/ hole is inoculated into six orifice plates, respectively sets 2 A group, it is set as administration group and non-administration group, administration group gives the Cetuximab (Erbitux) of 1ug/ml；After cultivating 72h, platform is expected Indigo plant dyeing calculates live cell fraction.The results are shown in Figure 6, and the c-Met/CAR-EGFRt group Cell viabilities of administration are 23.8%, no The c-Met/CAR-EGFRt group Cell viabilities of administration are 96.4%.It is 95% or more that NC groups, which are administered and motility rate is not administered,.Explanation The c-Met specific C AR-NK cells of band EGFRt switches prepared by embodiment 1 can be by giving Cetuximab (Erbitux) eventually Only it plays a role, and realizes that Chimeric antigen receptor immune response is controllable, and treatment side effect is few, and specificity is high.
Test four：
Antitumor activity detection and switch safety in c-Met specific C AR-NK multicellular animal bodies with EGFRt switches Detection
The human liver cancer HepG-2 cells of logarithmic growth phase are made single cell suspension after pancreatin digestion, will contain 1 × 107It is a The suspension 0.1mL of cancer cell is subcutaneously injected in nude mice scapular region.Experiment packet and treatment see the table below, and daily each group of observing is moved The variation of the diet of object, activity etc., the next day measure nude mice weight, observe changes of weight situation；Tumour was measured every 2 days most It the case where diameter (a) vertical greatly and maximum transverse diameter (b), observation tumour growth, is calculated according to formula：Knurl accumulates=1/12 π × a × b2。 (3) organize the 13rd day tumour inhibiting rate for calculating each group nude mice after treatment end, tumour inhibiting rate=(1- treatment group tumors average external volume/the moon Property control group tumor average volume) × 100%.
Experiment packet and treatment are as shown in table 6 below.
Table 6：Experiment packet and treatment
* FAC chemotherapy regimens：Fluorouracil 500mg/M2；Adriamycin 50mg/M2；Cyclophosphamide 500mg/M2, gives for first day Medicine, 21 days courses for the treatment of.
The experimental results showed that the c-Met specific C AR-NK cells with EGFRt switches carry out internal anti-tumor experiment hair Existing, each group nude mice survives, and using negative control group nude mice as reference, chemotherapy group nude mice weight loss, gross tumor volume reduces, but into Food and activity are reduced.
C-Met/CAR-EGFRt-NK treatment groups nude mice survival condition is better, and weight is without being decreased obviously, and tumour body Significantly smaller, the inhibitory rate to 76.0% of product.And switch safety test group nude mice survival condition is compared with c-Met/CAR-EGFRt- NK treatment groups are declined, and inhibitory rate is only 10.1%.Body weights and tumor control rate statistical result are shown in Table 7.
Table 7：The comparison of each group nude mice weight, gross tumor volume and tumour inhibiting rate
The above experimental result illustrates that the c-Met specific C AR-NK cells of the band EGFRt switches prepared can effectively inhibit The growth of in-vivo tumour, and switch with validity.Cetuximab can be used as " opening for Chimeric antigen receptor behavior in NK cells Close ", it realizes that Chimeric antigen receptor immune response is controllable, has a safety feature, treatment side effect is few, and specificity is high.
One or more of embodiments of the invention above described embodiment only expresses, description are more specific and detailed Carefully, but it cannot be construed as a limitation to the scope of the present invention.It should be pointed out that for the common skill of this field For art personnel, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to this hair Bright protection domain.Therefore, the protection domain of patent of the present invention should be determined by the appended claims.
Sequence table
<110>Shenzhen Mo Saier biomedicine developments in science and technology Co., Ltd
<120>Chimeric antigen receptor and its expressing gene with safety switch, the NK cells of its modification and application
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 218
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<400> 1
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp
1 5 10 15
Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Arg Asn Tyr Leu
20 25 30
Asn Trp Tyr Gln Gln Glu Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Asp Phe Ile Leu Thr Ile Ser Ser Leu Gln Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Val Thr Pro Leu Thr
85 90 95
Phe Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
100 105 110
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
115 120 125
Phe Ser Lys Tyr Asp Met Leu Trp Val Arg Gln Ala Pro Gly Lys Gly
130 135 140
Leu Glu Trp Val Ser Tyr Ile Tyr Pro Ser Gly Gly Leu Thr Glu Tyr
145 150 155 160
Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
165 170 175
Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
180 185 190
Val Tyr Tyr Cys Ala Arg Arg Ala Pro Arg Ser Leu Ser Phe Asp Ile
195 200 205
Trp Gly Gln Gly Thr Met Val Thr Val Ser
210 215
<210> 2
<211> 335
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<400> 2
Arg Lys Val Cys Asn Gly Ile Gly Ile Gly Glu Phe Lys Asp Ser Leu
1 5 10 15
Ser Ile Asn Ala Thr Asn Ile Lys His Phe Lys Asn Cys Thr Ser Ile
20 25 30
Ser Gly Asp Leu His Ile Leu Pro Val Ala Phe Arg Gly Asp Ser Phe
35 40 45
Thr His Thr Pro Pro Leu Asp Pro Gln Glu Leu Asp Ile Leu Lys Thr
50 55 60
Val Lys Glu Ile Thr Gly Phe Leu Leu Ile Gln Ala Trp Pro Glu Asn
65 70 75 80
Arg Thr Asp Leu His Ala Phe Glu Asn Leu Glu Ile Ile Arg Gly Arg
85 90 95
Thr Lys Gln His Gly Gln Phe Ser Leu Ala Val Val Ser Leu Asn Ile
100 105 110
Thr Ser Leu Gly Leu Arg Ser Leu Lys Glu Ile Ser Asp Gly Asp Val
115 120 125
Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr Ala Asn Thr Ile Asn Trp
130 135 140
Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys Thr Lys Ile Ile Ser Asn
145 150 155 160
Arg Gly Glu Asn Ser Cys Lys Ala Thr Gly Gln Val Cys His Ala Leu
165 170 175
Cys Ser Pro Glu Gly Cys Trp Gly Pro Glu Pro Arg Asp Cys Val Ser
180 185 190
Cys Arg Asn Val Ser Arg Gly Arg Glu Cys Val Asp Lys Cys Asn Leu
195 200 205
Leu Glu Gly Glu Pro Arg Glu Phe Val Glu Asn Ser Glu Cys Ile Gln
210 215 220
Cys His Pro Glu Cys Leu Pro Gln Ala Met Asn Ile Thr Cys Thr Gly
225 230 235 240
Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala His Tyr Ile Asp Gly Pro
245 250 255
His Cys Val Lys Thr Cys Pro Ala Gly Val Met Gly Glu Asn Asn Thr
260 265 270
Leu Val Trp Lys Tyr Ala Asp Ala Gly His Val Cys His Leu Cys His
275 280 285
Pro Asn Cys Thr Tyr Gly Cys Thr Gly Pro Gly Leu Glu Gly Cys Pro
290 295 300
Thr Asn Gly Pro Lys Ile Pro Ser Ile Ala Thr Gly Met Val Gly Ala
305 310 315 320
Leu Leu Leu Leu Leu Val Val Ala Leu Gly Ile Gly Leu Phe Met
325 330 335
<210> 3
<211> 654
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 3
atccagatga cccagtctcc atcctccctg tctgcatctg taggagacag agtcaccatc 60
acttgtcggg caagtcagag cattaggaac tatttaaatt ggtatcagca ggaaccaggg 120
aaagccccta agctcctgat ctatgctgca tccagtttgc aaagtggggt cccatcaagg 180
ttcagtggca gtggatctgg gacagacttc attctcacca tcagcagtct gcagcctgaa 240
gattttgcaa cttactactg tcaacagagt tacgttaccc cgctcacttt cggtggtggt 300
ggttctggcg gcggcggctc cggtggtggt ggatctcagc ctggtggttc tttacgtctt 360
tcttgcgctg cttccggatt cactttctct aagtacgata tgctttgggt tcgccaagct 420
cctggtaaag gtttggagtg ggtttcttat atctatcctt ctggtggcct tactgagtat 480
gctgactccg ttaaaggtcg cttcactatc tctagagaca actctaagaa tactctctac 540
ttgcagatga acagcttaag ggctgaggac acggccgtgt attactgtgc gagacgggct 600
ccccggtccc tttcttttga tatctggggc caagggacaa tggtcaccgt ctcc 654
<210> 4
<211> 1005
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 4
cgcaaagtgt gtaacggaat aggtattggt gaatttaaag actcactctc cataaatgct 60
acgaatatta aacacttcaa aaactgcacc tccatcagtg gcgatctcca catcctgccg 120
gtggcattta ggggtgactc cttcacacat actcctcctc tggatccaca ggaactggat 180
attctgaaaa ccgtaaagga aatcacaggg tttttgctga ttcaggcttg gcctgaaaac 240
aggacggacc tccatgcctt tgagaaccta gaaatcatac gcggcaggac caagcaacat 300
ggtcagtttt ctcttgcagt cgtcagcctg aacataacat ccttgggatt acgctccctc 360
aaggagataa gtgatggaga tgtgataatt tcaggaaaca aaaatttgtg ctatgcaaat 420
acaataaact ggaaaaaact gtttgggacc tccggtcaga aaaccaaaat tataagcaac 480
agaggtgaaa acagctgcaa ggccacaggc caggtctgcc atgccttgtg ctcccccgag 540
ggctgctggg gcccggagcc cagggactgc gtctcttgcc ggaatgtcag ccgaggcagg 600
gaatgcgtgg acaagtgcaa ccttctggag ggtgagccaa gggagtttgt ggagaactct 660
gagtgcatac agtgccaccc agagtgcctg cctcaggcca tgaacatcac ctgcacagga 720
cggggaccag acaactgtat ccagtgtgcc cactacattg acggccccca ctgcgtcaag 780
acctgcccgg caggagtcat gggagaaaac aacaccctgg tctggaagta cgcagacgcc 840
ggccatgtgt gccacctgtg ccatccaaac tgcacctacg gatgcactgg gccaggtctt 900
gaaggctgtc caacgaatgg gcctaagatc ccgtccatcg ccactgggat ggtgggggcc 960
ctcctcttgc tgctggtggt ggccctgggg atcggcctct tcatg 1005
<210> 5
<211> 787
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<400> 5
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15
Ala Phe Leu Leu Ile Pro Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
20 25 30
Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
35 40 45
Ser Ile Arg Asn Tyr Leu Asn Trp Tyr Gln Gln Glu Pro Gly Lys Ala
50 55 60
Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro
65 70 75 80
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ile Leu Thr Ile
85 90 95
Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser
100 105 110
Tyr Val Thr Pro Leu Thr Phe Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys
130 135 140
Ala Ala Ser Gly Phe Thr Phe Ser Lys Tyr Asp Met Leu Trp Val Arg
145 150 155 160
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Tyr Pro Ser
165 170 175
Gly Gly Leu Thr Glu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile
180 185 190
Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu
195 200 205
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Ala Pro Arg
210 215 220
Ser Leu Ser Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser
225 230 235 240
Pro Lys Leu Gly Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro
245 250 255
Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
260 265 270
Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
275 280 285
Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
290 295 300
Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Lys Arg Gly Arg Lys
305 310 315 320
Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr
325 330 335
Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu
340 345 350
Gly Gly Cys Glu Leu Arg Leu Val Pro Arg Gly Arg Gly Ala Ala Glu
355 360 365
Ala Ala Thr Arg Lys Gln Arg Ile Thr Glu Thr Glu Ser Pro Tyr Gln
370 375 380
Glu Leu Gln Gly Gln Arg Ser Asp Val Tyr Ser Asp Leu Asn Thr Gln
385 390 395 400
Arg Pro Tyr Tyr Lys Ser Pro Gly Gly Gly Ser Gly Glu Gly Arg Gly
405 410 415
Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro Gly Pro Met Leu
420 425 430
Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro Ala Phe
435 440 445
Leu Leu Ile Pro Arg Lys Val Cys Asn Gly Ile Gly Ile Gly Glu Phe
450 455 460
Lys Asp Ser Leu Ser Ile Asn Ala Thr Asn Ile Lys His Phe Lys Asn
465 470 475 480
Cys Thr Ser Ile Ser Gly Asp Leu His Ile Leu Pro Val Ala Phe Arg
485 490 495
Gly Asp Ser Phe Thr His Thr Pro Pro Leu Asp Pro Gln Glu Leu Asp
500 505 510
Ile Leu Lys Thr Val Lys Glu Ile Thr Gly Phe Leu Leu Ile Gln Ala
515 520 525
Trp Pro Glu Asn Arg Thr Asp Leu His Ala Phe Glu Asn Leu Glu Ile
530 535 540
Ile Arg Gly Arg Thr Lys Gln His Gly Gln Phe Ser Leu Ala Val Val
545 550 555 560
Ser Leu Asn Ile Thr Ser Leu Gly Leu Arg Ser Leu Lys Glu Ile Ser
565 570 575
Asp Gly Asp Val Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr Ala Asn
580 585 590
Thr Ile Asn Trp Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys Thr Lys
595 600 605
Ile Ile Ser Asn Arg Gly Glu Asn Ser Cys Lys Ala Thr Gly Gln Val
610 615 620
Cys His Ala Leu Cys Ser Pro Glu Gly Cys Trp Gly Pro Glu Pro Arg
625 630 635 640
Asp Cys Val Ser Cys Arg Asn Val Ser Arg Gly Arg Glu Cys Val Asp
645 650 655
Lys Cys Asn Leu Leu Glu Gly Glu Pro Arg Glu Phe Val Glu Asn Ser
660 665 670
Glu Cys Ile Gln Cys His Pro Glu Cys Leu Pro Gln Ala Met Asn Ile
675 680 685
Thr Cys Thr Gly Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala His Tyr
690 695 700
Ile Asp Gly Pro His Cys Val Lys Thr Cys Pro Ala Gly Val Met Gly
705 710 715 720
Glu Asn Asn Thr Leu Val Trp Lys Tyr Ala Asp Ala Gly His Val Cys
725 730 735
His Leu Cys His Pro Asn Cys Thr Tyr Gly Cys Thr Gly Pro Gly Leu
740 745 750
Glu Gly Cys Pro Thr Asn Gly Pro Lys Ile Pro Ser Ile Ala Thr Gly
755 760 765
Met Val Gly Ala Leu Leu Leu Leu Leu Val Val Ala Leu Gly Ile Gly
770 775 780
Leu Phe Met
785
<210> 6
<211> 2361
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 6
atgcttctcc tggtgacaag ccttctgctc tgtgagttac cacacccagc attcctcctg 60
atcccaatcc agatgaccca gtctccatcc tccctgtctg catctgtagg agacagagtc 120
accatcactt gtcgggcaag tcagagcatt aggaactatt taaattggta tcagcaggaa 180
ccagggaaag cccctaagct cctgatctat gctgcatcca gtttgcaaag tggggtccca 240
tcaaggttca gtggcagtgg atctgggaca gacttcattc tcaccatcag cagtctgcag 300
cctgaagatt ttgcaactta ctactgtcaa cagagttacg ttaccccgct cactttcggt 360
ggtggtggtt ctggcggcgg cggctccggt ggtggtggat ctcagcctgg tggttcttta 420
cgtctttctt gcgctgcttc cggattcact ttctctaagt acgatatgct ttgggttcgc 480
caagctcctg gtaaaggttt ggagtgggtt tcttatatct atccttctgg tggccttact 540
gagtatgctg actccgttaa aggtcgcttc actatctcta gagacaactc taagaatact 600
ctctacttgc agatgaacag cttaagggct gaggacacgg ccgtgtatta ctgtgcgaga 660
cgggctcccc ggtccctttc ttttgatatc tggggccaag ggacaatggt caccgtctcc 720
cccaagcttg gggcgaagcc caccacgacg ccagcgccgc gaccaccaac accggcgccc 780
accatcgcgt cgcagcccct gtccctgcgc ccagaggcgt gccggccagc ggcggggggc 840
gcagtgcaca cgagggggct ggacttcgcc tgtgatatct acatctgggc gcccttggcc 900
gggacttgtg gggtccttct cctgtcactg gttatcaccc tttacaaacg gggcagaaag 960
aaactcctgt atatattcaa acaaccattt atgagaccag tacaaactac tcaagaggaa 1020
gatggctgta gctgccgatt tccagaagaa gaagaaggag gatgtgaact gcggctggtc 1080
cctcgggggc gaggggctgc ggaggcagcg acccggaaac agcgtatcac tgagaccgag 1140
tcgccttatc aggagctcca gggtcagagg tcggatgtct acagcgacct caacacacag 1200
aggccgtatt acaaatcccc cgggggagga agcggagagg gcagaggaag tctgctaaca 1260
tgcggtgacg tcgaggagaa tcctggacct atgcttctcc tggtgacaag ccttctgctc 1320
tgtgagttac cacacccagc attcctcctg atcccacgca aagtgtgtaa cggaataggt 1380
attggtgaat ttaaagactc actctccata aatgctacga atattaaaca cttcaaaaac 1440
tgcacctcca tcagtggcga tctccacatc ctgccggtgg catttagggg tgactccttc 1500
acacatactc ctcctctgga tccacaggaa ctggatattc tgaaaaccgt aaaggaaatc 1560
acagggtttt tgctgattca ggcttggcct gaaaacagga cggacctcca tgcctttgag 1620
aacctagaaa tcatacgcgg caggaccaag caacatggtc agttttctct tgcagtcgtc 1680
agcctgaaca taacatcctt gggattacgc tccctcaagg agataagtga tggagatgtg 1740
ataatttcag gaaacaaaaa tttgtgctat gcaaatacaa taaactggaa aaaactgttt 1800
gggacctccg gtcagaaaac caaaattata agcaacagag gtgaaaacag ctgcaaggcc 1860
acaggccagg tctgccatgc cttgtgctcc cccgagggct gctggggccc ggagcccagg 1920
gactgcgtct cttgccggaa tgtcagccga ggcagggaat gcgtggacaa gtgcaacctt 1980
ctggagggtg agccaaggga gtttgtggag aactctgagt gcatacagtg ccacccagag 2040
tgcctgcctc aggccatgaa catcacctgc acaggacggg gaccagacaa ctgtatccag 2100
tgtgcccact acattgacgg cccccactgc gtcaagacct gcccggcagg agtcatggga 2160
gaaaacaaca ccctggtctg gaagtacgca gacgccggcc atgtgtgcca cctgtgccat 2220
ccaaactgca cctacggatg cactgggcca ggtcttgaag gctgtccaac gaatgggcct 2280
aagatcccgt ccatcgccac tgggatggtg ggggccctcc tcttgctgct ggtggtggcc 2340
ctggggatcg gcctcttcat g 2361

Claims (10)

1. a kind of Chimeric antigen receptor with safety switch, which is characterized in that including sequentially connected first signal peptide, c-Met Single-chain antibody, CD8 structural domains, 41BB intracellular domain, DAP12-ITAM structural domains, T2A, second signal peptide and transformation EGFRt；Wherein, the amino acid sequence of the c-Met single-chain antibodies is as shown in SEQ ID No.1, the ammonia of the EGFRt of the transformation Base acid sequence is as shown in SEQ ID No.2.
2. the Chimeric antigen receptor according to claim 1 with safety switch, which is characterized in that it is mono- to encode the c-Met The nucleotide sequence of chain antibody is as shown in SEQ ID No.3.
3. the Chimeric antigen receptor according to claim 1 with safety switch, which is characterized in that encode the transformation The nucleotide sequence of EGFRt is as shown in SEQ ID No.4.
4. the Chimeric antigen receptor according to claim 1 with safety switch, which is characterized in that the Chimeric antigen receptor For：
(a) protein that amino acid sequence forms shown in SEQ ID No.5；Or,
(b) by replacing, missing or adding one or several amino acid and tool in the amino acid sequence shown in SEQ ID No.5 There is the active protein derived from (a) of the Chimeric antigen receptor.
5. the Chimeric antigen receptor according to claim 1 or 4 with safety switch, which is characterized in that the chimeric antigen Receptor is：
(a) the nucleotide sequence coded obtained protein shown in SEQ ID No.6；Or,
(b) by replacing, missing or adding one or several bases and can in the nucleotide sequence shown in SEQ ID No.6 Coding obtains having the active protein derived from (a) of the Chimeric antigen receptor.
6. a kind of expressing gene, for expressing the Chimeric antigen receptor with safety switch, which is characterized in that the chimeric antigen by Body includes sequentially connected first signal peptide, c-Met single-chain antibodies, CD8 structural domains, 41BB intracellular domain, DAP12-ITAM Structural domain, T2A, second signal peptide and the EGFRt of transformation；Wherein, the amino acid sequence such as SEQ of the c-Met single-chain antibodies Shown in ID No.1, the amino acid sequence of the EGFRt of the transformation is as shown in SEQ ID No.2.
7. expressing gene according to claim 6, which is characterized in that the expressing gene is：
(a) nucleotide sequence as shown in SEQ ID No.6；Or,
(b) by replacing, missing or adding one or several bases and can in the nucleotide sequence shown in SEQ ID No.6 Coding obtains having the active nucleotide sequence of the Chimeric antigen receptor.
8. a kind of expression vector, which is characterized in that contain expressing gene as claimed in claims 6 or 7 in the expression vector.
9. a kind of NK cells of the Chimeric antigen receptor modification with safety switch, which is characterized in that being capable of table in the NK cells Up to having imported such as claim 6~7 in such as Claims 1 to 5 any one of them Chimeric antigen receptor or the NK cells Expression vector as claimed in claim 8 has been transfected in any one of them expressing gene or the NK cells.
10. as Claims 1 to 5 any one of them Chimeric antigen receptor, such as claim 6~7 any one of them are expressed Gene, expression vector as claimed in claim 8 or the Chimeric antigen receptor with safety switch is repaiied as claimed in claim 9 Application of the NK cells of decorations in preparing anti-tumor drug.
CN201810096080.3A 2018-01-31 2018-01-31 Chimeric antigen receptor with safety switch, expression gene thereof, NK cell modified by chimeric antigen receptor and application of chimeric antigen receptor Active CN108341881B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810096080.3A CN108341881B (en) 2018-01-31 2018-01-31 Chimeric antigen receptor with safety switch, expression gene thereof, NK cell modified by chimeric antigen receptor and application of chimeric antigen receptor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810096080.3A CN108341881B (en) 2018-01-31 2018-01-31 Chimeric antigen receptor with safety switch, expression gene thereof, NK cell modified by chimeric antigen receptor and application of chimeric antigen receptor

Publications (2)

Publication Number Publication Date
CN108341881A true CN108341881A (en) 2018-07-31
CN108341881B CN108341881B (en) 2020-08-18

Family

ID=62961766

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810096080.3A Active CN108341881B (en) 2018-01-31 2018-01-31 Chimeric antigen receptor with safety switch, expression gene thereof, NK cell modified by chimeric antigen receptor and application of chimeric antigen receptor

Country Status (1)

Country Link
CN (1) CN108341881B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111269925A (en) * 2019-03-15 2020-06-12 阿思科力(苏州)生物科技有限公司 ROBO1CAR-NK cell carrying suicide gene and preparation method and application thereof
CN112063639A (en) * 2019-06-10 2020-12-11 深圳市罗湖区人民医院 Double-signal chimeric antigen receptor and preparation method and application thereof
CN112080512A (en) * 2019-06-14 2020-12-15 深圳市罗湖区人民医院 CAR-NK (CAR-natural killer) with safety switch and preparation method thereof
CN111848797B (en) * 2020-07-20 2021-02-09 北京鼎成肽源生物技术有限公司 Single-chain antibody targeting c-Met, chimeric antigen receptor, recombinant vector, CAR-T cell and application
WO2021060932A1 (en) * 2019-09-26 2021-04-01 주식회사 헬릭스미스 Chimeric antigen receptor comprising anti c-met antibody or antigen binding fragment thereof, and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105384825A (en) * 2015-08-11 2016-03-09 南京传奇生物科技有限公司 Bispecific chimeric antigen receptor based on variable domains of heavy chain of heavy-chain antibody and application thereof
CN105418765A (en) * 2014-08-26 2016-03-23 西比曼生物科技（上海）有限公司 CD19 targeting chimeric antigen receptor and NKT cell, and preparation method thereof and applications thereof
CN105906720A (en) * 2016-05-16 2016-08-31 武汉汉密顿生物科技股份有限公司 Targeting chimeric antigen receptor modified immune cell as well as preparation method and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105418765A (en) * 2014-08-26 2016-03-23 西比曼生物科技（上海）有限公司 CD19 targeting chimeric antigen receptor and NKT cell, and preparation method thereof and applications thereof
CN105384825A (en) * 2015-08-11 2016-03-09 南京传奇生物科技有限公司 Bispecific chimeric antigen receptor based on variable domains of heavy chain of heavy-chain antibody and application thereof
CN105906720A (en) * 2016-05-16 2016-08-31 武汉汉密顿生物科技股份有限公司 Targeting chimeric antigen receptor modified immune cell as well as preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张欢: "基于2A 肽策略构建多基因表达载体的研究进展", 《中国生物工程杂志》 *
陈杰: "嵌合抗原受体T细胞介绍及抗肿瘤临床应用", 《中国细胞生物学学报》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111269925A (en) * 2019-03-15 2020-06-12 阿思科力(苏州)生物科技有限公司 ROBO1CAR-NK cell carrying suicide gene and preparation method and application thereof
CN111269925B (en) * 2019-03-15 2024-01-30 阿思科力(苏州)生物科技有限公司 ROBO1 CAR-NK cell carrying suicide gene and preparation method and application thereof
CN112063639A (en) * 2019-06-10 2020-12-11 深圳市罗湖区人民医院 Double-signal chimeric antigen receptor and preparation method and application thereof
CN112063639B (en) * 2019-06-10 2023-05-26 深圳市罗湖区人民医院 Double-signal chimeric antigen receptor and preparation method and application thereof
CN112080512A (en) * 2019-06-14 2020-12-15 深圳市罗湖区人民医院 CAR-NK (CAR-natural killer) with safety switch and preparation method thereof
WO2021060932A1 (en) * 2019-09-26 2021-04-01 주식회사 헬릭스미스 Chimeric antigen receptor comprising anti c-met antibody or antigen binding fragment thereof, and use thereof
CN111848797B (en) * 2020-07-20 2021-02-09 北京鼎成肽源生物技术有限公司 Single-chain antibody targeting c-Met, chimeric antigen receptor, recombinant vector, CAR-T cell and application

Also Published As

Publication number Publication date
CN108341881B (en) 2020-08-18

Similar Documents

Publication Publication Date Title
CN108341881A (en) Chimeric antigen receptor and its expressing gene with safety switch, the NK cells of its modification and application
CN110662834B (en) Method for culturing natural killer cells using transformed T cells
CN105624107B (en) Amplification method of multiple lymphocyte subsets and application thereof
CN109385403B (en) GPC 3-targeting CAR NK cells
CN105848484A (en) Polyclonal [Gamma] [delta] T cells for immunotherapy
CN106755088A (en) A kind of autologous CAR T cells preparation method and application
CN105296431B (en) The α β T cells and its suppression cancer purposes of tumor combination specificity gamma delta T CR genetic modifications
CN105950561A (en) Products and preparation method of double chimeric antigen receptor gene modified T lymphocyte targeting breast cancer stem cells
CN105873952A (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CN106591363A (en) Preparation method of universal heterologous CAR-T cells and application
CN109721659A (en) It is a kind of target CD19 Novel chimeric antigen receptor (CAR) and its application
CN105368859B (en) A kind of Chimeric antigen receptor hCD87-CAR and slow virus and plasmid and its application for being loaded with hCD87-CAR gene structure
CN107033248A (en) Recognize Chimeric antigen receptor and its application of carcinomebryonic antigen
CN113416260B (en) Claudin18.2-targeted specific chimeric antigen receptor cell and preparation method and application thereof
CN109055430A (en) A kind of preparation method for co-expressing IL18 and CCL19 albumen and targeting MUC1 gene C AR-T cell
CN107475275A (en) The T cell and its application that Chimeric antigen receptor and its expressing gene, the Chimeric antigen receptor of dual anti-former regulation are modified
CN101580817A (en) Method for preparing cell group containing cytokine-induced killing cell
CN107893055A (en) A kind of NK of specific chimeric antigen receptor genetic modification and its production and use
CN110423767A (en) Express Chimeric antigen receptor CAR gene and the application of solubility PD-1
CN107624119A (en) A kind of molecule, the cell for expressing it and its production and use
CN109293781A (en) The T cell and its application of Chimeric antigen receptor and its gene and recombinant expression carrier, the bis- targetings of CD19-CD20
CN105384826A (en) Cord blood nucleated cell for expressing chimeric antigen receptor and application of cord blood nucleated cell
CN108251442A (en) FLT3 Chimeric antigen receptors and its application
CN108395480A (en) Chimeric antigen receptor and its gene and recombinant expression carrier, CARHER2-NKT cells and its preparation method and application
CN108314739A (en) Multi signal Chimeric antigen receptor and its expressing gene, the NK cells of its modification and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant